Payment overview · 2025
General Payments
$234.34
10 reported records · 6 companies
Healthcare provider profile · identity verified
Katherine E Blalock, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BRYAN, TX · NPI 1083996177
Verified facts
What the public records show
CMS Open Payments records show Katherine E Blalock, M.D. received $234.34 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.22 | 22.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $50.86 | 21.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.43 | 21.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.52 | 14.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.74 | 11.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.57 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.34 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.22 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $50.86 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1011 | 220 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 634 | 109 |
| Lisinopril | Lisinopril | 506 | 121 |
| Losartan Potassium | Losartan Potassium | 411 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 395 | 94 |
| Furosemide | Furosemide | 357 | 61 |
| Carvedilol | Carvedilol | 352 | 65 |
| Eliquis | Apixaban | 323 | 50 |
| Gabapentin | Gabapentin | 298 | 70 |
| Metformin Hcl | Metformin Hcl | 293 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 51 |
| Potassium Chloride | Potassium Chloride | 256 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 59 |
| Sertraline Hcl | Sertraline Hcl | 189 | 40 |
| Omeprazole | Omeprazole | 162 | 36 |
| Ezetimibe | Ezetimibe | 158 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 49 |
| Trazodone Hcl | Trazodone Hcl | 156 | 25 |
| Metformin Hcl Er | Metformin Hcl | 155 | 42 |
| Montelukast Sodium | Montelukast Sodium | 153 | 24 |
| Nifedipine Er | Nifedipine | 151 | 33 |
| Donepezil Hcl | Donepezil Hcl | 145 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 22 |
| Simvastatin | Simvastatin | 133 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 130 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 48 |
| Jardiance | Empagliflozin | 127 | 29 |
| Tramadol Hcl | Tramadol Hcl | 120 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 20 |
| Levetiracetam | Levetiracetam | 111 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 28 |
| Mirtazapine | Mirtazapine | 103 | 15 |
| Ozempic | Semaglutide | 100 | 26 |
| Bupropion Xl | Bupropion Hcl | 98 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 95 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 19 |
| Memantine Hcl | Memantine Hcl | 89 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 21 |
| Divalproex Sodium | Divalproex Sodium | 85 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 81 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | suppressed |
| Aripiprazole | Aripiprazole | 74 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 74 | suppressed |
| Glipizide Er | Glipizide | 72 | 18 |
| Pregabalin | Pregabalin | 71 | 15 |
| Buspirone Hcl | Buspirone Hcl | 66 | 13 |
| Famotidine | Famotidine | 63 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 20 |
| Baclofen | Baclofen | 59 | suppressed |
| Trulicity | Dulaglutide | 59 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 19 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Torsemide | Torsemide | 54 | 12 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Glipizide | Glipizide | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 11 |
| Atenolol | Atenolol | 51 | 15 |
| Meloxicam | Meloxicam | 51 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 51 | suppressed |
| Allopurinol | Allopurinol | 49 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 27 |
| Spironolactone | Spironolactone | 49 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | suppressed |
| Mounjaro | Tirzepatide | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Prednisone | Prednisone | 39 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 12 |
| Scopolamine | Scopolamine | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 11 |
| Valacyclovir | Valacyclovir Hcl | 36 | 14 |
| Celecoxib | Celecoxib | 35 | 13 |
| Lactated Ringers | Ringer's Solution,lactated | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 17 |
| Klor-Con M20 | Potassium Chloride | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Trospium Chloride | Trospium Chloride | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | 11 |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 15 |
| Levemir | Insulin Detemir | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Finasteride | Finasteride | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Fluconazole | Fluconazole | 16 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Azithromycin | Azithromycin | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Haloperidol | Haloperidol | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.34 · 10 records | GlaxoSmithKline, LLC. | JARDIANCE, Kerendia, OTEZLA, REPATHA, TRELEGY ELLIPTA, VRAYLAR, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error